Botanical Solution announced it has closed another $7.6 million financing, as part of Series A, that will fund the commencement of in-house production of QS-21, pharmaceutical grade vaccine adjuvant. Using cost-effective and scalable proprietary methods, BSI will expand QS-21 use in broader vaccine applications.Botanical Solution, a Delaware Corporation, has a proprietary platform for sustainable and improved production of consistent, high quality Advanced Botanical Materials (ABM).

植物学解决方案宣布，作为A系列的一部分，它已经完成了另外760万美元的融资，这将为开始内部生产QS-21（药物级疫苗佐剂）提供资金。使用具有成本效益和可扩展的专有方法，BSI将扩大QS-21在更广泛的疫苗应用中的使用。特拉华州的一家公司Botanical Solution拥有一个专有平台，用于可持续和改进一致的高质量先进植物材料（ABM）的生产。

ABM-01 is the first ABM produced by the company, based on a plant called Quillaja saponaria. ABM-01 is the active ingredient used in two gold standard products, BSI's biopesticide Quillibrium and the vaccine adjuvant QS-21, used in a Shingles blockbuster vaccine, a recently launched RSV vaccine and a Malaria vaccine..

ABM-01是该公司基于一种名为Quillaja saponaria的植物生产的第一种ABM。ABM-01是两种金标准产品中使用的活性成分，BSI的生物农药Quillibrium和疫苗佐剂QS-21，用于带状疱疹重磅疫苗，最近推出的RSV疫苗和疟疾疫苗。。